United Kingdom

People: Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

9:00pm BST
Change (% chg)

$-0.15 (-1.95%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kinney, Gene 

Dr. Gene G. Kinney, Ph.D., is President, Chief Executive Officer, Director of the Company. Prior to that, he was our Chief Operating Officer for part of 2016, and prior to that he was our Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Senior Vice President of Pharmacological Sciences (from 2011 to 2012) and Vice President, Pharmacology (from 2009 to 2011) for Elan Pharmaceuticals, Inc; and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol-Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his BA from Bloomsburg University and his MA and PhD from Florida Atlantic University.

Basic Compensation

Total Annual Compensation, USD 520,833
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 4,627,410
Fiscal Year Total, USD 5,148,240

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 31,759 1,726,840.00
Name Fiscal Year Total

Lars Ekman


Gene Kinney


Tran Nguyen


Karin Walker


Wagner Zago


Carol Karp

As Of  31 Dec 2017